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Abstract
Aims/hypothesis We aimed to determine whether plasma lipo-
proteins, after leakage into the retina and modification by
glycation and oxidation, contribute to the development of di-
abetic retinopathy in a mouse model of type 1 diabetes.
Methods To simulate permeation of plasma lipoproteins into
retinal tissues, streptozotocin-induced mouse models of dia-
betes and non-diabetic mice were challenged with intravitreal
injection of human ‘highly-oxidised glycated’ low-density li-
poprotein (HOG-LDL), native- (N-) LDL, or the vehicle PBS.
Retinal histology, electroretinography (ERG) and biochemical
markers were assessed over the subsequent 14 days.
Results Intravitreal administration of N-LDL and PBS had no
effect on retinal structure or function in either diabetic or non-
diabetic animals. In non-diabetic mice, HOG-LDL elicited a
transient inflammatory response without altering retinal func-
tion, but in diabetic mice it caused severe, progressive retinal
injury, with abnormal morphology, ERG changes, vascular
leakage, vascular endothelial growth factor overexpression,
gliosis, endoplasmic reticulum stress, and propensity to
apoptosis.
Conclusions/interpretation Diabetes confers susceptibility to
retinal injury imposed by intravitreal injection of modified
LDL. The data add to the existing evidence that extravasated,
modified plasma lipoproteins contribute to the propagation of
diabetic retinopathy. Intravitreal delivery of HOG-LDL simu-
lates a stress known to be present, in addition to
hyperglycaemia, in human diabetic retinopathy once blood-
retinal barriers are compromised.
Keywords Diabetic retinopathy . Dyslipidaemia .
Lipoprotein . Oxidised LDL . Pathogenesis . Vascular
complications
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BAX Bcl2-associated X protein
BRB Blood-retinal barrier




GFAP Glial fibrillary acidic protein
HOG-LDL Highly-oxidised, glycated LDL
KDEL Amino acid sequence Lys-Asp-Glu-Leu
N-LDL Native LDL
ox-LDL Oxidised LDL
RPE Retinal pigment epithelium
VEGF Vascular endothelial growth factor
Introduction
Diabetic retinopathy remains a leading cause of new-onset
blindness in adults [1], but its pathogenesis is not fully under-
stood. It is known that ‘residual risks’ exist even after control-
ling for hyperglycaemia [2]. Among these, plasma lipopro-
teins have been implicated, as supported by numerous clinical
and epidemiological studies; see reviews [3–5] and some key
studies [6–14]. Most of these studies focus on standard mea-
sures of circulating lipids and lipoproteins, and in general,
they show associations between ‘dyslipidaemia’, for example
elevated plasma LDL-cholesterol or apolipoprotein B (apoB),
and the severity of diabetic retinopathy. Some studies have
gone further, addressing qualitative (and not just quantitative)
changes in plasma lipoproteins, including the extent of LDL
modification by oxidation [15]. We have previously reported
associations between diabetic retinopathy severity and aver-
age lipoprotein particle diameters and the distribution of ‘sub-
classes’ of HDL, LDL, and VLDL in the Diabetes Control and
Complications Trial/Epidemiology of Diabetes Interventions
and Complications (DCCT/EDIC) cohort [10]. Also in that
cohort, we found that circulating immune complexes contain-
ing oxidised LDL (ox-LDL) predicted severe diabetic retinop-
athy many years later [13]. Overall, however, associations
between plasma lipoproteins and diabetic retinopathy, al-
though statistically significant in population studies, are too
weak to define individual risk or prognosis, as recently
underlined in two detailed reports [14, 15].
We have hypothesised that despite these rather unimpres-
sive associations between plasma lipoproteins and diabetic
retinopathy, lipoproteins actually play a central role in diabetic
retinopathy progression, but one that is ‘hidden’, occurring in
tissue, and only operative after extravasation and modifica-
tion. In the retina, in contrast to arteries during atherogenesis,
leakage from plasma to tissue only occurs if the blood-retinal
barriers (BRBs) are compromised. Put simply, plasma
lipoprotein levels may be largely irrelevant to the retina if
BRBs are intact, and their effects following BRB breakdown
may depend more on the extent of leakage than on their plas-
ma concentrations. In support of this concept, we have ob-
served that intra-retinal deposits of apoB-100 (the main pro-
tein component of LDL and VLDL), ox-LDL and ox-LDL
immune complexes are entirely absent in healthy human ret-
inas, but present in diabetic retinas even before the onset of
clinical retinopathy, and thereafter in greater amounts com-
mensurate with diabetic retinopathy severity [16, 17].
Furthermore, we have consistently observed toxicity of LDL
(modified in vitro to simulate stresses found in vivo), towards
cultured human retinal cells, including capillary endothelial
cells, pericytes, retinal pigment epithelial (RPE) cells, and
Müller cells, promoting oxidative and endoplasmic reticulum
(ER) stresses, inflammation and death [17–24]; ox-LDL is
also injurious to neurons [25]. Based on these considerations,
we hypothesise that after extravasation into the retinal tissue,
lipoproteins becomemodified by glycation and oxidation and,
thus, become cytotoxic. In this way, episodes of initially tran-
sient, localised vascular leakage may lead to vicious cycles of
chronic pathology.
Rodent models are commonly used in diabetic retinopathy
research, but they have limitations. Rodents do not develop
the advanced, proliferative retinopathy that afflicts humans
[26]. Oxygen-induced retinopathy models in new-born ro-
dents exhibit neovascularisation, but the animals are not a
model of diabetes. Regarding a possible role of extravasated
lipoproteins in the propagation of diabetic retinopathy, a crit-
ical difference between rodents and humans lies in their lipo-
protein metabolism: rodents have substantially lower LDL
levels than humans and cholesterol is transported primarily
in HDL [27]. Therefore, rodent models of diabetes fail to
replicate the chronic exposure to extravasated, modified
LDL that we have demonstrated in human diabetic retinopa-
thy. In the present study, using intravitreal injection of human
LDL (with or without modification), we assessed the effects
on retinas in a mouse model of diabetes and in non-diabetic
mice.
Methods
AnimalsMale C57BL/6J mice (7–8 weeks old) were obtained
from Jackson Laboratory (Bar Harbor, ME, USA), and housed
on a 12/12 h dark-light cycle in a controlled environment (22.5
±0.5°C, 50±5% humidity) with access to food and water ad
libitum. After at least oneweek of acclimatisation, animals were
randomised into the study by weight. A model of type 1 diabe-
tes was induced with streptozotocin (50–55 mg/kg, daily for
5 days, i.p.; Enzo Life Sciences, Farmingdale, NY, USA);
non-diabetic controls received vehicle. Development of diabe-
tes (fasting blood glucose≥16.7mmol/l) was confirmed 28 days
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later, and mice were maintained for eight additional weeks be-
fore intravitreal injections. Animals that did not convert to dia-
betes or that later showed apparent intraocular injection injuries
were excluded, but otherwise all animals that consecutively
completed the study protocol were included. As far as possible,
the ocular outcome assessments described below were per-
formed using a ‘blinded’ study design. The study was approved
by the Institutional Animal Care and Use Committee of the
University of Oklahoma Health Sciences Center.
Human lipoprotein preparation As previously described
[19, 22], freshly pooled plasma was obtained from four to
six healthy, non-diabetic volunteers aged 20–40 years who
were taking neither prescribed medications nor antioxidant
vitamins. All donors gave informed consent; the study was
approved by the Institutional Review Board of University of
Oklahoma Health Sciences Center and was carried out in ac-
cordance with the Declaration of Helsinki as revised in 2008.
Native LDL (N-LDL; density 1.019–1.063 g/ml) was pre-
pared by sequential ultracentrifugation. To prepare highly-
oxidised glycated LDL (HOG-LDL), N-LDL was glycated
in 50 mmol/l glucose (72 h, 37°C) under antioxidant condi-
tions (1 mmol/l diethylenetriaminepentaacetic acid (DTPA;
Sigma-Aldrich, St Louis, MO, USA), 270 μmol/l EDTA, un-
der nitrogen), dialysed to remove glucose and antioxidants,
and then further oxidised in 10 μmol/l CuCl2 (24 h, 37°C).
After extensive dialysis, protein concentrations were quanti-
fied (Pierce BCA assay; ThermoFisher Scientific, Waltham,
MA, USA). The preparations were characterised by electro-
phoresis and tested to be free of endotoxin (Limulus
Amoebocyte Lysate assay, Bio-Whittaker, Walkersville, MD,
USA).
Intravitreal administration of LDL Mice were
anaesthetised using ketamine (100 mg/kg i.p.; Henry Schein
Animal Health, Dublin, OH, USA) and xylazine (10 mg/kg,
i.p.; Vedco, St. Joseph, MO, USA), then received intravitreal
administration of 1 μl N-LDL or HOG-LDL (5 μg protein/μl,
diluted in PBS), or PBS, using a 36-gauge needle/syringe
assembly (World Precision Instruments, Sarasota, FL, USA).
Both N-LDL and HOG-LDL were confirmed to be soluble in
rat vitreous humour ex vivo. In each animal, one eye was
injected with either N-LDL or HOG-LDL, and the other with
PBS as a control.
The intraocular kinetics of exogenous LDL is unclear; we
aimed to provide a target LDL concentration of approximately
0.5 μg protein/μl, assuming an average vitreous humour vol-
ume of 10 μl [28–30]. This approximates the LDL concentra-
tion in human plasma. We hypothesise that local ox-LDL
concentrations in diabetic retinas may be much higher, con-
sidering its non-uniform, patchy distribution [16, 17], as in
atherosclerotic plaques [31].
Electroretinography Full-field scotopic electroretinography
(ERG) was recorded at 3, 7, and 14 days after ocular injection,
using established methods [32, 33]. Briefly, after dark adapta-
tion overnight, mice were anaesthetised and maintained on a
37°C heating pad. The pupils were dilated with 2.5% phenyl-
ephrine (Paragon Bioteck, Portland, OR, USA) and 1%
tropicamide (Bausch & Lomb, Rochester, NY, USA) eye
drops. ERGs were recorded bilaterally and simultaneously
using gold wire electrodes placed on the cornea, with the
reference and ground electrodes positioned at the nasal fornix
and the tail, respectively.
Histology The eyes were fixed overnight in Perfix (20%
isopropanol [vol./vol.] and 2% trichloroacetic acid, 4% para-
formaldehyde and 2% zinc chloride [wt/vol]), and placed in
70% ethanol before paraffin embedding. Sagittal sections of
5 μm thickness were stained with haematoxylin and eosin.
Retinal albumin leakage Immunohistochemistry of extrava-
sated albumin was used to assess retinal vascular leakage, thus
avoiding potential interference from effects of exogenous
tracers on BRB function [34, 35]. Retinal sections were
deparaffinised and permeabilised with 0.5% (vol./vol.)
Triton X-100 for 10 min, followed by incubation with the
primary antibody (goat polyclonal anti-albumin, 1:400;
Novus Biologicals, Littleton, CO, USA) at 4°C overnight.
Alexa Fluor 488-conjugated polyclonal anti-goat IgG
(1:400) was used as a secondary ant ibody (Life
Technologies, Carlsbad, CA, USA). The antibodies were used
as per the manufacturer’s instructions. DAPI was used for
nuclear staining (Life Technologies, Carlsbad, CA, USA).
Immunofluorescence was detected under a Nikon E800 mi-
croscope (Nikon, Tokyo, Japan), analysed by ImageJ (https://
imagej.nih.gov/ij), with the background subtracted. Data were
analysed using a modified two sample median test for the
distribution of pixel intensities. For each eye, superior and
inferior sections were randomly selected and imaged at
magnification ×10. The total of all pixel intensity measures
from vitreous and retina (from the ganglion cell layer to outer
nuclear layer) was used as an index of vascular leakage.
Retinal flat mounts For further visualisation of vascular leak-
age, two labelled dextrans (FITC-dextran, 2000 kD and Texas
Red-dextran, 3 kD; 100 μl of 1:1 cocktail; Life Technologies,
Carlsbad, CA, USA) were administered by intra-cardiac injec-
tion to anaesthetised mice. After 10–15 min, retinas were
fixed, flat-mounted, and imaged using an Olympus
FluoView FV500 confocal microscope (Olympus, Center
Valley, PA, USA).
Western blots Retinas were homogenised with RIPA lysis
buffer (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
with the protein concentration determined (Pierce BCA assay;
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ThermoFisher). Total protein (30 μg) was resolved by 12%
SDS-PAGE and electrophoretically transferred to nitrocellu-
lose membranes (Bio-Rad, Hercules, CA, USA). Membranes
were blocked for 1 h with 5% (wt/vol.) non-fat milk in Tris-
buffered saline with Tween 20 (TBST), and incubated over-
night (4°C) with primary antibodies (Abcam, Cambridge,
MA, USA) against glial fibrillary acidic protein (GFAP;
1:5000), vascular endothelial growth factor (VEGF; 1:1000),
phosphorylated elF2α (p-elf2α; 1:500), amino acid sequence
Lys-Asp-Glu-Leu (KDEL; 1:2000) and Bcl2-associated X
protein (BAX; 1:1000) diluted in 5% BSA in TBST, followed
by incubation for 1 h at room temperature with horseradish
peroxidase (HRP)-conjugated secondary antibody (Vector
Laboratories, Burlingame, CA, USA), diluted 1:5000 with
5% (wt/vol.) milk (Bio-Rad). The antibodies were used as
per the manufacturer’s instructions. Signals were visualised
using the SuperSignal West Dura extended duration substrate
kit (ThermoFisher) and quantified by digital image analysis
(Syngene, Frederick, MD, USA). Blots were subsequently
stripped and re-probed with the β-actin antibody (1:5000;
Abcam) for normalisation.
Immunohistochemistry Retinal sections were deparaffinised,
blocked by 5% (vol./vol.) donkey serum (Sigma-Aldrich) in
1% (vol./vol.) Triton X-100/PBS for 1 h, and incubated over-
night at 4°C with the primary antibody (rabbit polyclonal anti-
GFAP, 1:1000 and mouse monoclonal anti-KDEL, 1:100;
Abcam). Alexa Fluor 555-conjugated anti-rabbit IgG
(1:4000) andAlexa Fluor 488-conjugated anti-mouse IgGwere
used as secondary antibodies (Life Technologies). The nuclei
were counterstained with either DAPI (Life Technologies) or
propidium iodide (Sigma-Aldrich). Images were captured by a
Nikon E800 Epifluoresence microscope.
Statistics data Statistics data are expressed as means ± SEM.
Statistical analyses were conducted by one-way ANOVA
followed by Newman–Keuls post hoc test using Prism 5
(GraphPad, La Jolla, CA, USA). p< 0.05 was considered
significant.
Results
Diabetes sensitised retinas to modified-LDL-induced inju-
ry in mice Fig. 1 shows representative retinal morphology
after intravitreal delivery of HOG-LDL vs N-LDL or PBS in
diabetic and non-diabetic mice. N-LDL or PBS had no appar-
ent effects on the retina, regardless of glycaemic status, and
diabetic animals had not, as yet, developed any apparent pa-
thology. In non-diabetic mice, HOG-LDL induced a transient,
mild infiltration of immune cells in the photoreceptor and
ganglion cell layers on day 7, which resolved by day 14
(Fig. 1a). In contrast, in diabetic mice, HOG-LDL triggered
extensive inflammation with progressive disruption in all ret-
inal layers (Fig. 1b): on day 3, infiltrating cells were detectable
in the ganglion cell layer and vitreous; on day 7, more inflam-
matory cell infiltrations extended into the vitreous (see elec-
tronic supplementary material [ESM] Fig. 1), associated with
diffuse photoreceptor damage and swelling of RPE cells; and
on day 14, retinal injury became more extensive, with severe
disorganisation of retinal architecture. The data suggest that
diabetes renders an apparently normal retina highly suscepti-
ble to HOG-LDL-induced injury.
Modified LDL impaired retinal function in diabetic, but
not non-diabetic, mice ERGs were conducted to determine
the functional consequences of modified LDL on the retina
(Fig. 2). In general agreement with the morphologic findings,
ERG responses in diabetic mice after intravitreal
Fig. 1 Haematoxylin and eosin stained retinal sections after intravitreal
injection of HOG-LDL vs N-LDL and PBS in non-diabetic and diabetic
mice. (a) In non-diabetic mice, PBS and N-LDL did not affect retinal
morphology; HOG-LDL elicited a transient inflammatory response on
day 7 in the innermost layer of retina. (b) In diabetic retinas, PBS and
N-LDL again had no effects, but HOG-LDL caused major structural
disruption: marked inflammation and exudation were present by day 3,
adjacent to the inner limiting membrane and vitreous; by day 14, injury
extended throughout the retina. The rosette-like formations in the outer
retina on day 14 reflect the loss of association between neural retina and
the RPE layer. Magnification ×20; scale bar 100 μm
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administration of PBS or N-LDL were normal and similar to
those in non-diabetic animals. In non-diabetic mice, intravit-
real delivery of HOG-LDL did not significantly affect the
ERG when compared with PBS and N-LDL, but in diabetic
animals, HOG-LDL induced significant reductions in both the
photoreceptor and second-order neuronal functions at days 7
and 14 vs PBS or N-LDL controls.
Modified LDL increased retinal vascular permeability in
diabetic mice We employed two techniques to assess the in-
tegrity of BRBs. First, we quantified the extravasated endog-
enous albumin within the retina and vitreous. In non-diabetic
mice, albumin staining was observed in the ganglion cell layer
only, and there were no significant differences between treat-
ment groups (Fig. 3a, c). In contrast, intravitreal injection of
HOG-LDL vs N-LDL or PBS in diabetic mice increased the
presence of albumin in the retina and vitreous, reaching sta-
tistical significance on day 7 and a trend of increase on days 3
and 14 (Fig. 3b, d). Second, we assessed retinal leakage of two
fluorescein markers in retinal flat mounts from diabetic ani-
mals (Fig. 4). Again, no apparent leakage of either FITC-
dextran (2000 kD) or Texas Red-dextran (3 kD) was observed
following PBS or N-LDL administration. In contrast, HOG-
LDL resulted in detectable extravasation as early as 3 days,
Fig. 2 Effects of intravitreal
injection of HOG-LDL vs N-LDL
and PBS on ERG in non-diabetic
and diabetic mice. Scotopic ERGs
were recorded at light intensities
from −2.7 to +2.8 log10 cd s/m2.
Stimulus-response curves (a, c)
and maximal amplitudes (b, d)
are shown for a-waves (a, b) and
for b-waves (c, d) after intravitreal
administration of HOG-LDL
(red), N-LDL (green) or PBS
(blue). In non-diabetic mice,
HOG-LDL had no effects other
than a slightly enhanced b-wave
response vs N-LDL on day 3. In
diabetic mice, HOG-LDL caused
significant reductions in
amplitude of a- and b-waves on
days 7 (vs PBS) and 14 (vs PBS
and N-LDL). Data are presented
as means ± SEM, n= 5–6 per
treatment. *p< 0.05 and
**p< 0.01 vs PBS or N-LDL
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becoming increasingly severe at days 7 and 14, especially
with the 3 kD marker. Leakage of both fluoresceins in the
retinas of HOG-LDL treated diabetic mice appeared to be
scattered and patchy, resembling clinical diabetic retinopathy.
Modified LDL induced retinal inflammation, ER stress
and pro-apoptosis in diabetic mice To understand the mo-
lecular pathology of modified LDL-induced retinal injury in
diabetes, we explored alterations in protein markers for glial
activation (GFAP), angiogenesis/vascular permeability
(VEGF), ER stress (KDEL and p-eIF2α) and apoptosis
propensity (BAX) in mouse retina. HOG-LDL had broadly
similar effects to N-LDL in non-diabetic mice (Fig. 5a), but
Fig. 3 Albumin leakage in the retina and vitreous of non-diabetic and
diabetic mice after intravitreal injection of HOG-LDL. Representative
immunostaining of albumin (green) and DAPI (blue) on days 3, 7 and
14 post intravitreal injection of HOG-LDL vs N-LDL and PBS in (a)
non-diabetic and (b) diabetic mice. Magnification ×10; scale bar 100 μm.
Leakage was quantified in combined retina and vitreous from (c) non-
diabetic and (d) diabetic mice using ImageJ. Data are expressed as mean
± SEM, n= 3–4 animals per treatment. *p< 0.05 vs PBS or N-LDL.
PBS: white bar; N-LDL: grey bar; HOG-LDL: black bar
Fig. 4 Vascular leakage of fluorescein markers in retinal flat mounts of
diabetic mice after intravitreal injection of HOG-LDL. FITC-dextran
(2000 kDa, green) and Texas Red-dextran (3 kDa, red) were administered
intracardially to anaesthetised diabetic mice 3–14 days after intravitreal
injection of (a) PBS, (b) N-LDL, and (c) HOG-LDL. Retinal flat mounts
were prepared after 10–15 min. Leakage of both fluorescein markers in
the retina of HOG-LDL injected diabetic mice appeared patchy, resem-
bling clinical features of diabetic retinopathy. Magnification ×20; scale
bar 100 μm
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tended to induce retinal expression of GFAP, VEGF, KDEL,
p-eIF2α, and BAX in diabetic animals (Fig. 5b), reaching
significance in the case of VEGF (see also Fig. 5c–g). Some
of the markers, including VEGF, p-eIF2α, KDEL and BAX,
also showed an apparent time-dependency, i.e. their retinal
levels increased progressively from day 3 to day 14 (Fig. 5d,
e, f, g). Immunohistochemistry showed that, in diabetic mice
only, HOG-LDL induced GFAP expression in cells that were
morphologically characteristic of Müller cells (Fig. 6). HOG-
LDL also upregulated KDEL in diabetic retinas, with in-
creased staining in the ganglion cell layer, the inner nuclear
layer, and the RPE layer, as compared with PBS or N-LDL
(Fig. 7). This suggests that modified LDL injures not only
retinal vessels, but also neural and RPE cells, potentially con-
tributing to diabetic retinopathy by affecting multiple retinal
cell types.
Discussion
We evaluated, for the first time, the effects of normal and
modified LDL given by intravitreal injection on the diabetic
retina. We showed that in the presence, but not in the absence,
of short duration diabetes (i.e., 12 weeks), mouse retinas be-
came highly sensitive to the injurious insult of HOG-LDL, but
that normal LDL had little effect. Specifically, HOG-LDL
altered the retinal architecture and impaired retinal function
as measured by ERG, vascular leakage, VEGF expression,
inflammation, ER stress, and propensity to apoptosis; effects
that replicate some features of human clinical diabetic retinop-
athy [36]. Thus, these data provide in vivo proof-of-concept
that lipoproteins, when extravasated and modified, have im-
portant and dire consequences in the propagation of diabetic
retinopathy, belying the relatively weak associations between
circulating levels and diabetic retinopathy.
Rodents have low endogenous LDL levels, and we consid-
ered chronic intravascular infusion of either human or mouse
LDL (with or without modification) to be unsatisfactory for
both practical and immunologic reasons [37]. Our goal was to
Fig. 5 Western blot analyses of retinal biomarkers for inflammation, ER
stress and pro-apoptosis after intravitreal injection of HOG-LDL vs N-
LDL and PBS in non-diabetic and diabetic mice. Representative western
blots for GFAP, VEGF, p-elF2α, KDEL and Bax expression 3–14 days
after intravitreal injection of HOG-LDL (lanes 3, 6, 9) vs N-LDL (lanes 2,
5, 8) and PBS (lanes 1, 4, 7) in (a) non-diabetic and (b) diabetic mice.
(c–g) Quantitative analyses of blots; relative fold change vs PBS controls
at respective time points. PBS: white bar; N-LDL: grey bar; HOG-LDL:
black bar. Data are expressed as mean ± SEM; n = 3–4 per treatment.
*p< 0.05 and **p < 0.01 vs PBS or N-LDL
Fig. 6 GFAP immunofluorescence in non-diabetic and diabetic retinas
after intravitreal injection of HOG-LDL. Extensive glial activation was
observed in diabetic, but not in non-diabetic, mouse retinas 7–14 days
after HOG-LDL injection, shown as abundant GFAP immunostaining
(red) in Müller cell end feet, with radial processes stained intensely
throughout inner and outer retina. DAPI (blue) is indicated on the left
side of each panel to show the location of the retinal nuclear layers. GCL,
ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer.
Scale bar: 100 μm
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simulate the accumulation of intra-retinal modified LDL and
to understand its contribution to the pathogenesis of diabetic
retinopathy.We chose the intravitreal route to access the retina
in a manner analogous to therapeutic approaches in humans. It
should be mentioned that, to our knowledge, the endogenous
vitreous levels of N-LDL or ox-LDL in diabetic humans have
not been documented in the literature, either in the presence or
absence of retinopathy. It has been reported that non-diabetic
human and bovine aqueous humour contains only HDL, but
not LDL [38]. However, in view of our findings of progressive
extravasation and modification of LDL in the diabetic retina
[16, 17], both N-LDL and modified LDL may exist in the
vitreous of diabetic patients.
An important question concerns possible immune re-
sponses to human LDL when introduced to the mouse. We
consider such effects do not explain the present findings, first
because retinal injury was induced by HOG-LDL but not by
N-LDL, and second because HOG-LDL only induced retinop-
athy in diabetic but not in non-diabetic animals. Ocular im-
mune privilege [39] might have a role. However, it should be
noted that modified LDL, with its altered immunogenicity,
does trigger immune responses in humans, resulting in im-
mune complexes which are implicated in vascular disorders.
In the DCCT/EDIC cohort, we found that higher plasma
levels of ox-LDL immune complexes predicted risk of diabet-
ic retinopathy in type 1 diabetes [13]. In patients with type 2
diabetes, higher circulating levels of autoantibodies against
malondialdehyde-modified apoB-100 were associated with
diabetic retinopathy [11]. It is estimated that 95% of ox-LDL
in circulation may be immune-complexed [40]. Recently, we
reported the presence of ox-LDL immune complexes in hu-
man diabetic retinas, and in cell culture; these exhibited great-
er toxicity than non-complexed ox-LDL towards pericytes
[17]. Thus, immune responses to ox-LDL are involved in
diabetic retinopathy, but are unlikely to explain the present
findings. In the present study, HOG-LDL induced inflamma-
tory cell infiltration in both diabetic and non-diabetic animals,
but the response was much more dramatic in the diabetic
animals, and, therefore, the effect cannot be attributed to im-
munologic response to a lipoprotein from a different species.
One intriguing finding from this study is that diabetes ap-
pears to ‘prime’ the retina to the injurious effects of HOG-
LDL. The dramatic response to HOG-LDL suggests that sub-
clinical changes had already occurred, even though the retina
appeared to be normal. The existence of subclinical injury in
diabetes agrees with clinical observations; retinas remain ap-
parently normal for over 5 years [41], after which the devel-
opment and rate of progression of diabetic retinopathy vary
widely among individuals [42]. A seminal study by Engerman
and Kern [43] showed that in diabetic dogs, poor glycaemic
control caused subclinical damage, the progression of which
could not be prevented by subsequent good glycaemic control.
One plausible explanation for our data is that diabetes
(characterised by hyperglycaemia) upregulates CD36 in reti-
nal cells [44], which mediates the toxicity of modified LDL
[17]: this is consistent with the observed synergistic effects of
glucose and lipids in macrophages via the CD36 receptor in
atherosclerotic lesions [45]. Thus the data support a potential-
ly important role of extravasated lipoproteins, in addition to
hyperglycaemia, in the propagation of diabetic retinopathy.
Loss of BRB integrity is a critical feature of early diabetic
retinopathy [36]. In this study, intravitreal administration of
HOG-LDL elicited extensive BRB breakdown in diabetic, but
not in non-diabetic mice. Retinal leakage of fluorescein
markers appeared scattered and patchy, as is seen in clinical
diabetic retinopathy. There was also evidence of injury to the
RPE layer, suggesting that both inner and outer BRBs were
compromised. These effects were seen even though the LDL-
related stress ‘approached’ the retinal vessels from the outside,
not from the plasma. They were accompanied by progressive-
ly elevated VEGF in the retina over the two week timeframe
studied, which likely contributed to the higher vascular per-
meability. Considering the short duration of this study, the
present model simulates only the pre-proliferative changes
of diabetic retinopathy. It would be of interest to see whether
this increase in VEGF is sustained in the longer term, after
repetitive or continuing exposure to HOG-LDL, and if this
might induce neovascularisation (as is seen in proliferative
diabetic retinopathy of humans) in the rodent model. Taking
into account these in vivo data and our earlier observations in
human retinal vascular cells [17–24], there is now strong
Fig. 7 Expression of KDEL in retinal sections of diabetic mice 7 days
after intravitreal injection of HOG-LDL. Retinal sections from diabetic
mice were stained with antibody against KDEL (green) and nuclei were
counterstained by propidium iodide (PI, red). KDEL staining was in-
creased in the ganglion cell layer (GCL), inner nuclear layer (INL), and
RPE layer, but not in the outer nuclear layer (ONL), in diabetic retinas
after intravitreal injection of HOG-LDL vs N-LDL or PBS.Magnification
×40; scale bar 50 μm
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evidence that lipoprotein leakage and modification may cause
further loss of BRB integrity, and thus constitute an important
positive feedback loop propagating retinal injury.
We also studied some additional biochemical markers in
mouse retina that reflect known features of diabetic retinopa-
thy, including glial activation, ER stress and pro-apoptosis
[46]. HOG-LDL enhanced these processes in diabetic vs
non-diabetic mice. Interestingly, retinal ER stress and BAX
increased progressively during the two weeks of observation.
Thus, the data are in agreement with our earlier findings in
cultured human retinal cells exposed to HOG-LDL [17, 20,
22–24], and with studies in the retinas of diabetic patients [16,
23, 24].
Potential limitations include: (1) intravitreal injection may
not accurately mimic the continuous LDL extravasation around
retinal vessels; (2) only a single LDL dose was studied, and
future studies should define an optimal, pathophysiologically
relevant dose range; (3) the variables, including duration of
diabetes before LDL challenge and that after injection, require
optimisation; and (4) the mechanisms underlying the potentiat-
ing effects of HOG-LDL when combined with diabetes require
investigation.
In conclusion, our study shows that modified LDL, if pres-
ent in the retina at early stages of diabetes, significantly accel-
erates the progression of retinal injury and recapitulates many
features of human diabetic retinopathy. It supports the hypoth-
esis that, in addition to hyperglycaemia, and despite rather
weak associations between plasma lipoproteins and human
diabetic retinopathy, LDL (and presumably other lipoproteins)
plays an important but ‘hidden’ role in diabetic retinopathy.
Improved means to detect early vascular leakage and
‘glycoxidative/lipoxidative’ damage at the tissue and molecu-
lar levels may have value in diabetic retinopathy management.
The work also provides feasibility to investigate the relative
contribution of modified lipids and hyperglycaemia to diabet-
ic retinopathy using an animal model that employs a simple
intravitreal injection approach.
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